rTMS for Cerebellar Ataxia in Children

NCT ID: NCT07211490

Last Updated: 2025-10-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-01

Study Completion Date

2028-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dysfunction of the cerebellum can result in cerebellar ataxia (CA), typically marked by symptoms such as movement incoordination, gait instability, articulation disorder, oculomotor and swallowing difficulties. Children affected by paediatric cerebellar ataxia (PCA) often suffer from an array of motor symptoms, affecting their quality of life and psychosocial well-being. It was estimated that PCA affects 26/100,000 children worldwide for both genetic and acquired causes. Epidemiological data on PCA, however, are absent in the Hong Kong population.

PCAs comprise a varied group of cerebellar development disorders, marked by impaired balance and motor coordination (e.g., dysmetria and tremor) when performing voluntary movement. Clinical symptoms in children with PCA are related to lesioned localization - focal disorder of the cerebellar vermis leads to truncal instability, head titubation, and nystagmus; while lesioned cerebellar hemispheres results in ataxia gait (wide-staggering gait, tend to fall towards the affected side). These clinical symptoms result in functional difficulties involving balance and walking, reaching, grasping and manipulation, oculomotor and speech domains. Abnormalities of motor excitability have been reported in patients with cerebellar lesions - the motor threshold was found to be raised in the motor cortex contralateral to a hemi-cerebellar lesion.

With no effective pharmacological treatments available, rehabilitation serves as the primary treatment approach. Even though adaptive learning is affected by cerebellar lesion, motor learning is still possible via exercise interventions. Interventions may include compensatory (educate strategies to compensate for impairment) or restorative approaches (improve functions through training). While exercise interventions have been explored as a potential therapeutic approach for paediatric patients with cerebellar lesions or degeneration, the current evidence lacks robust, high-quality randomized controlled trials (RCTs) to substantiate their efficacy.

Existing evidence shows that cerebellar outputs project to several cortical areas, including the primary motor cortex (M1). CA patients with lesions in structures of the cerebellar efferent pathway exhibit reduced inhibition in the motor cortex. Selective modulation of the efferent pathways may offer an additional means of modulating cortical activity, thus improve motor coordination abilities in CA patients. With the development of non-invasive brain stimulation (NIBS) techniques, more research has been conducted using NIBS as treatment modalities for patients with CA. The most used NIBS techniques include repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS). Repetitive transcranial magnetic stimulation (rTMS) enables to modulate cortical excitability focally in conscious subjects; low-frequency stimulation (e.g., 1 Hz) is known to suppress cortical excitability, while higher frequencies (\> 5 Hz) induce facilitation. These changes in excitability occur not only at the site of stimulation but also at other distant interconnected sites of a network. Both the excitatory stimulation and inhibitory stimulation approaches were adopted in existing adult studies. Paediatric patients with cerebellar lesions-caused by stroke, tumour, or genetic conditions-are thought to share the same pathophysiological basis as adults. Using contra-lesional inhibitory rTMS, França et al. demonstrated that the intervention is safe and feasible for adult patients with CA, showing a reduction in ataxic symptoms. Despite promising results in the adult population, it is still unclear whether rTMS can relieve ataxic symptoms and improve motor performance in children with CA.

To date, no studies have been published on the effects of rTMS on improving ataxic symptoms in children with cerebellar ataxia. However, emerging evidence suggests its potential utility. Using rTMS of 1 Hz to stimulate the cerebellar hemisphere ipsilateral to the ataxic side combined with mirror therapy, Cha et al. demonstrated that there was improvement in functional mobility as measured by 6-minute walk test and the timed up and go test. Supporting the feasibility of rTMS in paediatric motor rehabilitation, our pilot RCT (HKWC UW 23-492) found that contra-lesional inhibitory rTMS over M1 combined with motor training is safe and effective in improving motor performance in children with cerebral palsy. Comparative studies in older adults suggest that cerebellar rTMS was more effective than M1 rTMS for motor learning and the consolidation, likely due to the unique role of cerebellum in the integration and processing of multimodal sensory inputs to refine motor planning. These findings highlight the cerebellum as a promising neuromodulatory target for motor rehabilitation, warranting further investigation in paediatric cerebellar ataxia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To address the research gap, our study aims to use low frequency rTMS over the contra-lesional cerebellum in children with cerebellar ataxia. We aim to measure the reduction in ataxic symptoms, the improvement in motor performance functionally as well as using neuroimaging. We hypothesize that low frequency rTMS applied to the contra-lesional cerebellum will lead to reduced ataxic symptoms as measured by ataxia rating scales, improved motor abilities as measured by motor assessment scales, as well as showed improvement in structural as well as functional connectivity. Our study aims to use low frequency stimulation to the contra-lesional cerebellum which will be a safer option as no stimulation will be given to affected brain regions with abnormal brain changes or scarring. This study will be a prospective and randomized controlled study and aims to assess the treatment effect, and the sustainment of the treatment effect, of a 10-day treatment paradigm consisting of: 1) contra-lesional inhibitory rTMS and 2) post-treatment motor training in reducing ataxic symptoms in children with cerebellar ataxia. This study also aims to investigate the underlying neurophysiological mechanisms responsible for the rTMS treatment effect.

The specific hypotheses to be tested include:

* rTMS followed by motor training will reduce ataxic symptoms as reflected by ataxia rating scales (SARA and ICARS) to a greater extent than training alone in children with cerebellar ataxia.
* rTMS followed by motor training will lead to better quality of life (QoL) than training alone.
* rTMS followed by motor training will result in increased cortical plasticity compared to training alone.
* rTMS followed by motor training will result in brain microstructural changes demonstrated by DKI compared to training alone.
* rTMS followed by motor training will result in improvement in structural and functional connectivity demonstrated by DKI and resting state fMRI compared to training alone.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebellar Ataxia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Interventional rTMS group

The intervention group will receive 1 Hz rTMS for 15 minutes, followed by 1.5 hours of motor training.

Group Type EXPERIMENTAL

Repetitive Transcranial Magnetic Stimulation

Intervention Type DEVICE

1 Hz rTMS for 20 minutes, followed by 1.5 hours of motor training.

Sham rTMS group

The sham group will not receive any Hz of rTMS for 20 minutes, followed by 1.5 hours of motor training.

Group Type SHAM_COMPARATOR

Sham Repetitive Transcranial Magnetic Stimulation

Intervention Type DEVICE

Sham Hz rTMS for 20 minutes, followed by 1.5 hours of motor training.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Repetitive Transcranial Magnetic Stimulation

1 Hz rTMS for 20 minutes, followed by 1.5 hours of motor training.

Intervention Type DEVICE

Sham Repetitive Transcranial Magnetic Stimulation

Sham Hz rTMS for 20 minutes, followed by 1.5 hours of motor training.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged ≥ 4 years old - 18 years old fulfilling the following criteria: 1) diagnosis of cerebellar ataxia based on clinical history and neurological examination; 2) cerebellar lesion seen by MRI; 3) IQ ≥ 50 to ensure sufficient cognitive capacity for comprehending and adhering to motor training protocols.

Exclusion Criteria

* Patients will be excluded if they have: 1) Sensory ataxia with etiologies involving the peripheral nerves or posterior columns of the spinal cord, 2) Any contra-indications to rTMS, 3) Severe spasticity (defined as a score of 4 in the Modified Ashworth Scale) and contractures, 4) Uncontrollable epilepsy defined as the occurrence of seizures despite the use of at least one anti-epileptic drug (AED) in adequate dose, 5) History of Botulinum toxin A injection or upper limb casting in previous 6 months, and 6) Cerebellar ataxia resulting from genetic conditions.
Minimum Eligible Age

4 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The University of Hong Kong

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Winnie Wan Yee Tso (Dr)

Clinical Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The University of Hong Kong

Hong Kong, Hong Kong, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Wan Yee Winnie Tso Professor, MBBS

Role: CONTACT

+85222554295

Chai Yin Charlie Fan Miss, OT, BSc

Role: CONTACT

+85222554375

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Wan Yee Winnie Tso Professor, MBBS

Role: primary

+85222554295

Chai Yin Charlie Fan Miss, OT, BSc

Role: backup

+85222554375

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

rTMSCAHKU

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

TDCS-RTMS Intervention for Motor Function
NCT07257601 NOT_YET_RECRUITING NA